Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma

Clinics in Dermatology

Volumn 27, Issue 6, 2009, Pages 603-613

  Ray, Swagatam ^a   Chhabra, Arvind ^a   Mehrotra, Shikhar ^b   Chakraborty, Nitya G ^a   Ribas, Antoni ^c   Economou, James ^c   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CANCER VACCINE; DENDRITIC CELL VACCINE; EPITOPE; IMMUNOLOGICAL ADJUVANT; IPILIMUMAB; MANGANESE TETRAKIS(4 BENZOIC ACID)PORPHYRIN; MELANOMA ANTIGEN; MELANOMA VACCINE; PEPTIDE VACCINE; PORPHYRIN DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSTIMULATION; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; FORECASTING; HUMANS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PEPTIDES; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 70350351072     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2008.09.019     Document Type: Article

References (29)

1. Mukherji B., Chakraborty N.G., Yamasaki S., et al. Induction of antigen specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A 92 (1995) 8079-8082
2. Ribas A., Butterfield L.H., Glasoy J.A., and Economou J.S. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21 (2003) 2414-2432
3. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
4. Ehrlich P. Nederlandsch tijdscrift voor geneeskunde: Uber den jetzigne stand der karzinom-forschung. Weekblad Jaargang Eerst Heft 5 (1909) 273-290
5. Mukherji B. Molecular basis for tumor immunity. In: Bertino J.R. (Ed). Encyclopedia of cancer, volume 3 (2002), Academic Press, Inc, Orlando 197-212
6. Mukherji B., and MacAlister T.J. Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med 158 (1983) 240-245
7. Knuth A., Danowski B., Oettgen H.F., and Old L.J. T cell mediated cytotoxicity against autologous malignant melanoma: analysis with Inteerleukin-2 dependent T cell cultures. Proc Natl Acad Sci U S A 81 (1984) 3511-3515
8. Van der Bruggen P., Traversari P., Chomez P., et al. A gene encoding n antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 183 (1996) 725-729
9. Traversari C., van der Bruggen P., Luescher I.F., et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176 (1992) 1453-1457
10. Brenner D., Krammer P.H., and Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol 66 (2008) 52-64
11. Mehrotra S., Chhabra A., Chattopadhyay S., Dorsky D., Chakraborty N.G., and Mukherji B. Rescuing epitope specific cytolytic T lymphocytes from activation induced cell death by SP6000125, an inhibitor of Jun- N-terminal kinase: implication in cancer immunotherapy. J Immunol 173 (2004) 6017-6024
12. Mehrotra S., Chhabra A., Hegde U., Chakraborty N.G., and Mukherji B. Inhibition of c-Jun N-terminal kinase rescues influenza epitope specific human cytolytic T lymphocytes from activation induced cell death. J Leuk Biol 81 (2007) 539-547
13. Lenardo M.J. Molecular regulation of T lymphocyte homeostasis in the healthy and diseased immune system. Immunol Res 27 (2003) 387-398
14. Chhabra A., Mehrotra S., Chakraborty N.G., Dorsky D.I., and Mukherji B. Activation induced cell death of human melanoma epitope specific primary cytolytic T lymphocytes mediated by the release of mitochondrial apoptosis inducing factor. Eur J Immunol 3 (2006) 3167-3174
15. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
16. Barber DL Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
17. Gershon R.K., and Kondo K. Infectious immunological tolerance. Immunol 21 (1971) 903-914
18. North R.J. Down-regulation of the antitumor immune response. Adv Cancer Res 45 (1985) 1-43
19. Mukherji B., Wilhelm S.A., Guha A., and Ergin M.T. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136 (1986) 1888-1892
20. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-549
21. Chattopadhyay S., Chakraborty N.G., and Mukherji B. Regulatory T cell and tumor immunity. Cancer Immunol Immunother 54 (2005) 1153-1161
22. Chattopadhyay S., Mehrotra S., Chhabra A., Chakraborty N.G., and Mukherji B. Effect of CD4+CD25+ and CD4+CD25- regulatory T cells on the activation and expansion of self epitope and non-self epitope specific CTL precursors, in vitro. J Immunol 176 (2004) 984-990
23. Nagaraj S., and Gabrilovich D. Myeloid-derived suppressor cells. Adv Exp Med Biol 601 (2007) 213-223
24. Marigo I., Dolcetti L., Serafini P., Zanovello P., and Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222 (2008) 162-169
25. Sprent J., and Surh C.D. Generation and maintenance of memory T cells. Curr Opin Immunol 13 (2001) 248-254
26. Kaplan B.L., Tu D.C., Clay T.M., and Nishimura M.I. Redirecting T lymphocyte specificity using T cell receptor genes. Int Rev Immunol 170 (2003) 4881-4885
27. Morris E.C., Tsallios A., Bendle G.M., Xue S., and Stauss H.J. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A 102 (2005) 7934-7939
28. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that mediated by tumor cells. Annu Rev Immunol 5 (2007) 267-296
29. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998